| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000033911 |
| Receipt No. | R000037635 |
| Scientific Title | Analysis of allogenic stem cell transplantation for primary immunodeficiency using TRUMP data |
| Date of disclosure of the study information | 2018/12/01 |
| Last modified on | 2022/01/19 (Ver. 4) |
| Basic information | ||
| Public title | Analysis of allogenic stem cell transplantation for primary immunodeficiency using TRUMP data | |
| Acronym | Analysis of allo-HCT for PIDs in Japan | |
| Scientific Title | Analysis of allogenic stem cell transplantation for primary immunodeficiency using TRUMP data | |
| Scientific Title:Acronym | Analysis of allo-HCT for PIDs in Japan | |
| Region |
|
|
| Condition | ||
| Condition | Primary immunodeficiency | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | In order to improve hematopoietic cell transplantation (HCT) for primary immunodeficiencies (PIDs), we clarify the significance, efficacy and the risks of HCT, optimal donor selection, the choice of conditioning regimens, and management guidelines for adverse events by analyzing the data of patients with PIDs who have received HCT in Japan using PIDJ and TRUMP data. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Others |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Overall survival/ event-free survival in patients with PID after HCT |
| Key secondary outcomes | We divide the patients into following subgroups; different periods of years, disease categories according to International Union of Immunological Societies; IUIS classification, pre-HCT status of complications; infection, autoimmune disease or autoinflammatory diseases, conditioning regimen; myeloablative, reduced intensity or nothing, and donor sources. We analyze survival, adverse events and long-term immunological reconstitution (i.e. post-transplant chimerism and secession of immunoglobulin supplementation) in each subgroup.
In addition, we identify the factors contributing to survival by multivariate analysis, as well as the risks for post-HCT adverse events such as graft-versus host disease, infection or the late complications. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The patients with PID in TRUMP registration who have received HCT from January 1974 to December 2016 | |||
| Key exclusion criteria | The patients whose TRUMP data are insufficient for analysis. | |||
| Target sample size | 800 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University | ||||||
| Division name | Department of Pediatrics and Developmental Biology | ||||||
| Zip code | |||||||
| Address | Yushima 1-5-45, Bunkyo-ku, Tokyo, Japan | ||||||
| TEL | 03-5803-5249 | ||||||
| tmorio.ped@tmd.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Tokyo Medical and Dental University | ||||||
| Division name | Department of Pediatrics | ||||||
| Zip code | |||||||
| Address | Yushima 1-5-45, Bunkyo-ku, Tokyo, Japan | ||||||
| TEL | 03-5803-5249 | ||||||
| Homepage URL | |||||||
| smiyped@tmd.ac.jp | |||||||
| Sponsor | |
| Institute | Tokyo Medical and Dental University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ministry of Health, Labor and Welfare |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Observational study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037635 |